Ceres Pharma: what changed
Position among the sector peers
Sector benchmark: create a free account or sign in to use this tool.
You see every sector peer as a dot per ratio, with the company in two financial years and every ratio over five years against the sector.
What moved between 2024 and 2025
Largest movements
- Financial fixed assets +€46.6m
up €46.6m (+27.6%), from €168.7m to €215.3m
of which Affiliated companies: +€46.6m
- Current investments +€7.5m
new in 2025: €7.5m
- Cash -€3.2m
down €3.2m (-88.9%), from €3.6m to €395,847
mainly Investment in fixed assets (net) (-€47.0m) and Net result for the year (-€14.4m)
- Debts after one year +€47.4m
up €47.4m (+27.0%), from €175.3m to €222.7m
- Profit (loss) carried forward -€14.4m
down €14.4m (-38.2%), from -€37.6m to -€51.9m
- Other debts +€11.2m
up €11.2m (+115%), from €9.7m to €20.9m
- Trade debts +€5.9m
up €5.9m (+45.3%), from €13.1m to €19.1m
- Financial charges +€2.7m
up €2.7m (+15.8%), from €17.3m to €20.0m
of which Financial charges: +€2.1m
- Other operating income +€1.4m
up €1.4m (+101%), from €1.4m to €2.7m
- Services and other goods +€837,895
up €837,895 (+8.3%), from €10.0m to €10.9m
- Other operating charges +€457,661
up €457,661 (+54.7%), from €837,195 to €1.3m
- Staff costs -€414,044
down €414,044 (-9.3%), from €4.5m to €4.1m
Change in the result, 2024 to 2025
For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.
Derived cash bridge
The bridge is derived from the 2024 and 2025 balance sheets and the 2025 result. There is no filed cash-flow statement. You see where the money came from and where it went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €214,693,622 | €265,887,679 | +€51.2m | +23.8% |
| Formation expenses | 20 | €3,227,023 | €3,148,239 | -€78,784 | -2.4% |
| Fixed assets | 21/28 | €178,328,121 | €222,302,369 | +€44.0m | +24.7% |
| Intangible fixed assets | 21 | €8,986,497 | €6,642,591 | -€2.3m | -26.1% |
| Tangible fixed assets | 22/27 | €644,414 | €357,867 | -€286,546 | -44.5% |
| Plant, machinery and equipment | 23 | €261,461 | €252,042 | -€9,419 | -3.6% |
| Assets under construction and advance payments | 27 | €382,953 | €105,825 | -€277,127 | -72.4% |
| Financial fixed assets | 28 | €168,697,210 | €215,301,911 | +€46.6m | +27.6% |
| Affiliated companies | 280/1 | €168,684,752 | €215,292,648 | +€46.6m | +27.6% |
| Participating interests | 280 | €141,339,752 | €170,102,335 | +€28.8m | +20.3% |
| Amounts receivable | 281 | €27,345,000 | €45,190,313 | +€17.8m | +65.3% |
| Other financial fixed assets | 284/8 | €12,459 | €9,263 | -€3,196 | -25.7% |
| Amounts receivable and cash guarantees | 285/8 | €12,459 | €9,263 | -€3,196 | -25.7% |
| Current assets | 29/58 | €33,138,478 | €40,437,071 | +€7.3m | +22.0% |
| Stocks and contracts in progress | 3 | €6,793,163 | €8,639,921 | +€1.8m | +27.2% |
| Stocks | 30/36 | €6,793,163 | €8,639,921 | +€1.8m | +27.2% |
| Raw materials and consumables | 30/31 | €60,673 | €62,475 | +€1,802 | +3.0% |
| Goods purchased for resale | 34 | €6,732,490 | €8,577,446 | +€1.8m | +27.4% |
| Amounts receivable within one year | 40/41 | €20,223,283 | €22,353,088 | +€2.1m | +10.5% |
| Trade receivables | 40 | €5,946,363 | €7,023,597 | +€1.1m | +18.1% |
| Other amounts receivable | 41 | €14,276,920 | €15,329,492 | +€1.1m | +7.4% |
| Current investments | 50/53 | - | €7,500,000 | +€7.5m | |
| Other investments | 51/53 | - | €7,500,000 | +€7.5m | |
| Cash at bank and in hand | 54/58 | €3,551,221 | €395,847 | -€3.2m | -88.9% |
| Deferred charges and accrued income | 490/1 | €2,570,811 | €1,548,215 | -€1.0m | -39.8% |
| Total equity and liabilities | 10/49 | €214,693,622 | €265,887,679 | +€51.2m | +23.8% |
| Equity | 10/15 | €12,801,257 | -€1,550,308 | -€14.4m | |
| Contributions | 10/11 | €50,375,235 | €50,375,235 | = | 0.0% |
| Capital | 10 | €50,375,235 | €50,375,235 | = | 0.0% |
| Issued capital | 100 | €50,375,235 | €50,375,235 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€37,573,977 | -€51,925,543 | -€14.4m | -38.2% |
| Amounts payable | 17/49 | €201,892,365 | €267,437,987 | +€65.5m | +32.5% |
| Amounts payable after more than one year | 17 | €175,330,000 | €222,715,000 | +€47.4m | +27.0% |
| Financial debts | 170/4 | €175,330,000 | €222,715,000 | +€47.4m | +27.0% |
| Credit institutions | 173 | €175,330,000 | €222,715,000 | +€47.4m | +27.0% |
| Amounts payable within one year | 42/48 | €23,480,008 | €40,591,460 | +€17.1m | +72.9% |
| Trade debts | 44 | €13,108,873 | €19,051,453 | +€5.9m | +45.3% |
| Suppliers | 440/4 | €13,108,873 | €19,051,453 | +€5.9m | +45.3% |
| Taxes, remuneration and social security | 45 | €665,858 | €684,488 | +€18,630 | +2.8% |
| Taxes | 450/3 | €89,149 | €34,743 | -€54,406 | -61.0% |
| Remuneration and social security | 454/9 | €576,709 | €649,745 | +€73,036 | +12.7% |
| Other amounts payable | 47/48 | €9,705,277 | €20,855,519 | +€11.2m | +115% |
| Accrued charges and deferred income | 492/3 | €3,082,357 | €4,131,528 | +€1.0m | +34.0% |
| Operating income | 70/76A | €36,453,686 | €38,055,278 | +€1.6m | +4.4% |
| Turnover | 70 | €35,048,862 | €35,316,546 | +€267,685 | +0.8% |
| Other operating income | 74 | €1,361,775 | €2,738,732 | +€1.4m | +101% |
| Non-recurring operating income | 76A | €43,050 | - | -€43,050 | |
| Operating charges | 60/66A | €35,705,605 | €38,068,954 | +€2.4m | +6.6% |
| Goods for resale, raw materials and consumables | 60 | €16,223,260 | €16,477,937 | +€254,677 | +1.6% |
| Purchases | 600/8 | €16,752,463 | €18,060,803 | +€1.3m | +7.8% |
| Change in stocks: decrease (increase) | 609 | -€529,203 | -€1,582,866 | -€1.1m | -199% |
| Services and other goods | 61 | €10,049,919 | €10,887,814 | +€837,895 | +8.3% |
| Remuneration, social security and pensions | 62 | €4,467,808 | €4,053,765 | -€414,044 | -9.3% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €3,263,411 | €3,061,741 | -€201,670 | -6.2% |
| Write-downs on stocks, contracts in progress and trade receivables: additions (reversals) | 631/4 | €76,807 | -€263,107 | -€339,914 | |
| Other operating charges | 640/8 | €837,195 | €1,294,856 | +€457,661 | +54.7% |
| Non-recurring operating charges | 66A | €787,205 | €2,555,947 | +€1.8m | +225% |
| Operating profit (loss) | 9901 | €748,081 | -€13,676 | -€761,757 | |
| Financial income | 75/76B | €6,068,343 | €5,688,314 | -€380,029 | -6.3% |
| Recurring financial income | 75 | €6,068,343 | €5,688,314 | -€380,029 | -6.3% |
| Income from financial fixed assets | 750 | €2,814,903 | €4,213,260 | +€1.4m | +49.7% |
| Other financial income | 752/9 | €3,253,440 | €1,475,053 | -€1.8m | -54.7% |
| Financial charges | 65/66B | €17,270,894 | €20,008,215 | +€2.7m | +15.8% |
| Recurring financial charges | 65 | €17,270,894 | €19,355,195 | +€2.1m | +12.1% |
| Debt charges | 650 | €17,235,411 | €19,309,017 | +€2.1m | +12.0% |
| Other financial charges | 652/9 | €35,483 | €46,178 | +€10,695 | +30.1% |
| Non-recurring financial charges | 66B | - | €653,020 | +€653,020 | |
| Profit (loss) for the period before taxes | 9903 | -€10,454,470 | -€14,333,577 | -€3.9m | -37.1% |
| Income taxes | 67/77 | €12,973 | €17,988 | +€5,015 | +38.7% |
| Taxes | 670/3 | €12,973 | €17,988 | +€5,015 | +38.7% |
| Profit (loss) for the period | 9904 | -€10,467,443 | -€14,351,566 | -€3.9m | -37.1% |
| Profit (loss) for the period to be appropriated | 9905 | -€10,467,443 | -€14,351,566 | -€3.9m | -37.1% |
Value
latest balance sheet 31-12-2025 · indication, not a valuation or adviceIt files consolidated accounts. This indication rests only on its own accounts, without the subsidiaries. The value of the subsidiaries is therefore not in this range.
Indicative value of the equity
Indication, not a valuation or adviceMidpoint €0 · adjusted equity only
Capitalisation rate 12% result over 3 years, excluding non-recurring income and charges earnings weight 50% revaluation €0 other adjustment €0 EBITDA multiple
The filed figures and these assumptions give no positive value. The adjusted equity and the average result are both zero or negative.
Part of the calculation comes out below zero. A shareholding is never worth less than zero, so the floor is zero.
Adjusted equity
- Equity (10/15)
- -€1,550,308
- Formation expenses (20)
- -€3,148,239
- Intangible fixed assets (21)
- -€6,642,591
- Revaluation of assets
- €0
- Deferred tax on the revaluation
- €0
- Other adjustment
- €0
- Adjusted equity
- -€11.3m
Capitalised earnings
- 2025
- -€14,351,566
- excluding non-recurring income and charges
- -€11,142,598
- 2024
- -€10,467,443
- excluding non-recurring income and charges
- -€9,723,288
- 2023
- -€6,271,588
- excluding non-recurring income and charges
- -€5,029,077
- 2022
- -€4,564,419
- excluding non-recurring income and charges
- -€1,898,038
- 2021
- -€2,591,903
- excluding non-recurring income and charges
- -€709,033
- Average result, excluding non-recurring income and charges
- -€8,631,655
- Divided by the capitalisation rate
- 14% / 12% / 10%
- Capitalised earnings
- not meaningful, as the average result is zero or negative
Your EBITDA multiple
- EBITDA 2025
- €3,048,065
- Net financial debt
- €214,819,153
- Your multiple
- -
- Value with your multiple
- -
Net financial debt is the sum of financial debts after one year, the part due within the year and short-term financial debts, less cash and current investments.
Limits of the indication
- Checked holds no market prices or comparable transactions.
- Anything after the latest accounts and items off the balance sheet (guarantees, leases, disputes) are left out.
- Checked does not know the real value of buildings, stock and receivables. Enter your own revaluation or adjustment for it.
- The owner's role in the business, synergies for a buyer and the tax consequences of a sale are left out.
For a valuation to base a decision on, go to a company auditor or a certified accountant.
Next steps
Calculation and sources
Source: filed annual accounts (NBB) and main activity (KBO). The movements compare the financial years ended 31 December 2024 and 31 December 2025. Green is a favourable move for that line, red an unfavourable one. The value is an indication, not a valuation or advice. Prepared on 9 November 2026 via checked.be.